LINC01847: A Potential Drug Target and Biomarker (G101927766)

Target Name: LINC01847

NCBI ID: G101927766

LINC01847

Other Name(s): Long intergenic non-protein coding RNA 1847 | long intergenic non-protein coding RNA 1847

LINC01847: A Potential Drug Target and Biomarker

Non-Protein-Coding RNAs (NP-C RNAs) have emerged as a promising area of research in recent years due to their diverse functions in various cellular processes. One of the classes of NP-C RNAs is the Long Intergenic Non-Protein-Coding RNAs (LINC01847), which have been identified in various organisms and are characterized by their ability to transcribe from genomic long non-coding regions. LINC01847 has been shown to play important roles in various cellular processes, including cell growth, differentiation, and RNA processing and stability.

The LINC01847 gene, located on chromosome 16 at position 1847, encodes a RNA molecule of approximately 210 nucleotides. Despite its short length, LINC01847 is capable of encoding a wide range of functional RNA products. Several studies have characterized the LINC01847 RNA using various techniques, such as RNA sequencing and bioinformatics analysis, and have identified its unique features, such as a conserved stem-loop structure and a specific binding site for certain transcription factors.

One of the most promising aspects of LINC01847 is its potential as a drug target. The LINC01847 gene has been shown to be involved in various cellular processes that are important for human health, including cell growth, angiogenesis, and inflammation. Additionally, LINC01847 has been implicated in the development and progression of various diseases, such as cancer and neurodegenerative disorders.

The potential drug targets for LINC01847 are vast and varied. For example, LINC01847 has been shown to be involved in the regulation of cell cycle progression, which is a critical process for the development and maintenance of cancer cells. Additionally, LINC01847 has been shown to be involved in the regulation of cell adhesion, which is important for the development and maintenance of various tissues and organs.

Another potential drug target for LINC01847 is its role in the regulation of inflammation. LINC01847 has been shown to be involved in the regulation of various immune and inflammatory responses, which are important for maintaining human health. Additionally, LINC01847 has been implicated in the development and progression of various inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis.

The identification of potential drug targets for LINC01847 is an important step in the development of new treatments for various diseases. By targeting LINC01847 and its associated pathways, researchers can gain insights into the underlying mechanisms of these diseases and develop new treatments that can improve the health and well-being of humans.

In conclusion, LINC01847 is a promising candidate for drug targeting due to its unique functions and the potential benefits it can provide for human health. Further research is needed to fully understand the role of LINC01847 in various cellular processes and to develop effective treatments for the associated diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1847

The "LINC01847 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01847 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets